Table 2.
Compliance and completion rates for the QLQ-C30, QLQ-OES18, and EQ-5D in HRQoL analysis population.
| Time point | Compliance |
Completion |
||
|---|---|---|---|---|
| Sintilimab plus chemotherapy (N = 340) | Placebo plus chemotherapy (N = 349) | Sintilimab plus chemotherapy (N = 340) | Placebo plus chemotherapy (N = 349) | |
| EORTC QLQ-C30 | ||||
| Baseline | 340 (100%) | 349 (100%) | / | / |
| Week 6 | 305/320 (95.3%) | 318/330 (96.4%) | 305 (89.7%) | 318 (91.1%) |
| Week 12 | 283/300 (94.3%) | 272/284 (95.8%) | 283 (83.2%) | 272 (77.9%) |
| Week 18 | 252/266 (94.7%) | 208/230 (90.4%) | 252 (74.1%) | 208 (59.6%) |
| Week 24 | 220/232 (94.8%) | 178/190 (93.7%) | 220 (64.7%) | 178 (51.0%) |
| Week 30 | 175/188 (93.1%) | 139/149 (93.3%) | 175 (51.5%) | 139 (39.8%) |
| Week 36 | 138/145 (95.2%) | 108/110 (98.2%) | 138 (40.6%) | 108 (30.9%) |
| Week 42 | 117/126 (92.9%) | 72/77 (93.5%) | 117 (34.4%) | 72 (20.6%) |
| Week 48 | 110/117 (94.0%) | 53/54 (98.1%) | 110 (32.4%) | 53 (15.2%) |
| Week 60 | 95/103 (92.2%) | 38/39 (97.4%) | 95 (27.9%) | 38 (10.9%) |
| EORTC QLQ-OES18 | ||||
| Baseline | 340 (100%) | 349 (100%) | / | / |
| Week 6 | 305/320 (95.3%) | 318/330 (96.4%) | 305 (89.7%) | 318 (91.1%) |
| Week 12 | 283/300 (94.3%) | 272/284 (95.8%) | 283 (83.2%) | 272 (77.9%) |
| Week 18 | 253/266 (95.1%) | 208/230 (90.4%) | 253 (74.4%) | 208 (59.6%) |
| Week 24 | 219/232 (94.4%) | 178/190 (93.7%) | 219 (64.4%) | 178 (51.0%) |
| Week 30 | 175/188 (93.1%) | 139/149 (93.3%) | 175 (51.5%) | 139 (39.8%) |
| Week 36 | 138/145 (95.2%) | 107/110 (97.3%) | 138 (40.6%) | 107 (30.7%) |
| Week 42 | 117/126 (92.9%) | 71/77 (92.2%) | 117 (34.4%) | 71 (20.3%) |
| Week 48 | 111/117 (94.9%) | 53/54 (98.1%) | 111 (32.6%) | 53 (15.2%) |
| Week 60 | 95/103 (92.2%) | 37/39 (94.9%) | 95 (27.9%) | 37 (10.6%) |
| EQ-5D-5L | ||||
| Baseline | 340 (100%) | 347 (99.4%) | / | / |
| Week 6 | 305/320 (95.3%) | 317/330 (96.1%) | 305 (89.7%) | 317 (90.8%) |
| Week 12 | 282/300 (94.0%) | 272/284 (95.8%) | 282 (82.9%) | 272 (77.9%) |
| Week 18 | 253/266 (95.1%) | 206/230 (89.6%) | 253 (74.4%) | 206 (59.0%) |
| Week 24 | 220/232 (94.8%) | 177/190 (93.2%) | 220 (64.7%) | 177 (50.7%) |
| Week 30 | 174/188 (92.6%) | 139/149 (93.3%) | 174 (51.2%) | 139 (39.8%) |
| Week 36 | 138/145 (95.2%) | 108/110 (98.2%) | 138 (40.6%) | 108 (30.9%) |
| Week 42 | 117/126 (92.9%) | 71/77 (92.2%) | 117 (34.4%) | 71 (20.3%) |
| Week 48 | 111/117 (94.9%) | 53/54 (98.1%) | 111 (32.6%) | 53 (15.2%) |
| Week 60 | 95/103 (92.2%) | 38/39 (97.4%) | 95 (27.9%) | 38 (10.9%) |